[vc_row full_width=”stretch_row” equal_height=”yes” row_reverse_mobile=”1″ css=”.vc_custom_1587741074594{background-image: url(http://www.lacmedical.com/wp-content/uploads/2020/04/banner-new-12345.jpg?id=5970) !important;background-position: center !important;background-repeat: no-repeat !important;background-size: cover !important;}”][vc_column width=”1/2″ css=”.vc_custom_1571386030743{padding-top: 10% !important;padding-right: 10% !important;padding-bottom: 10% !important;padding-left: 10% !important;}”][vc_column_text]
Biomime Morph™
Sirolimus Eluting Coronary Stent System[/vc_column_text][basel_button align=”left” title=”Contact Us” link2=”url:http%3A%2F%2Fwww.lacmedical.com%2Fcontact-us%2F|||”][/vc_column][vc_column width=”1/2″ css=”.vc_custom_1587659178993{padding-top: 30% !important;padding-right: 30% !important;padding-bottom: 30% !important;padding-left: 30% !important;background-image: url(http://www.lacmedical.com/wp-content/uploads/2020/04/BIOMIME-MORPH-1.png?id=5887) !important;background-position: center !important;background-repeat: no-repeat !important;background-size: cover !important;}” el_class=”sinproimg”][/vc_column][/vc_row][vc_row][vc_column][vc_empty_space height=”50px”][/vc_column][/vc_row][vc_row][vc_column][vc_tta_tabs style=”modern” shape=”square” spacing=”10″ gap=”1″ alignment=”center” active_section=”1″ no_fill_content_area=”true”][vc_tta_section title=”Overview” tab_id=”1571308447375-84a59bd5-7ddc”][vc_row_inner equal_height=”yes” content_placement=”middle”][vc_column_inner width=”1/2″ css=”.vc_custom_1587386732536{background-color: #f4f4f7 !important;background-position: center !important;background-repeat: no-repeat !important;background-size: cover !important;}”][basel_counter label=”STENT THROMBOSIS” value=”0.3″ el_class=”percentagesym”][vc_empty_space][basel_counter label=”MACE AT 12 MONTHS IN BIOMIME MORPH MULTICENTER STUDY” value=”2″ el_class=”percentagesym”][vc_empty_space][basel_counter label=”FREEDOM FROM TARGET LESION FAILURE (TLF) AT 6 MONTHS IN MORPH INDIA STUDY” value=”99.4%” el_class=”percentagesym”][/vc_column_inner][vc_column_inner width=”1/2″ css=”.vc_custom_1571372435523{padding-top: 10% !important;padding-right: 10% !important;padding-bottom: 10% !important;padding-left: 10% !important;background-color: #156db2 !important;background-position: center !important;background-repeat: no-repeat !important;background-size: cover !important;}”][vc_column_text basel_color_scheme=”light”]
BIOMIME MORPH
Proven benefits of BioMime, now available as a tapered stent system. Treat long diffused lesions with a single stent – one and done.
Long diffused lesions are typically treated through multiple overlapping stents, which are associated with higher rate of restenosis/ revascularization.
Biomime MorphTM tapers as per vessel anatomy, it helps avoid multiple stent placement thus reducing the probability of fracture and restenosis.
Biomime MorphTM is a Sirolimus Eluting Coronary Stent System with an ultra-thin 65 µm strut thickness. This next generation SES has a Novel Hybrid Design with closed cells (on both ends of the stent) & open cells (in the middle) – this allows for Morphology Mediated Expansion for adequate conformability and lesser edge dissections.
BioPoly Biodegradable Polymer: 2µm low thickness, stable and elastic polymer
Stent design with non-linear S links & Y connectors allows for high flexibility and adequate side branch access.
Strut width variability ensures optimal radial strength. [/vc_column_text][/vc_column_inner][/vc_row_inner][vc_row_inner equal_height=”yes” content_placement=”middle”][vc_column_inner width=”1/2″ css=”.vc_custom_1571372435523{padding-top: 10% !important;padding-right: 10% !important;padding-bottom: 10% !important;padding-left: 10% !important;background-color: #156db2 !important;background-position: center !important;background-repeat: no-repeat !important;background-size: cover !important;}”][vc_column_text basel_color_scheme=”light”]
Benefits
- Avoids overlapping and associated restenosis and revascularization.
- Tapers as per vessel anatomy.
- Reduces procedural time as single stent is deployed.
- Economical – one stent versus use of multiple overlapping stents.
- Avoids excessive radiation and contrast.
[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/2″ css=”.vc_custom_1587386732536{background-color: #f4f4f7 !important;background-position: center !important;background-repeat: no-repeat !important;background-size: cover !important;}”][vc_single_image image=”5889″ img_size=”full” alignment=”center”][/vc_column_inner][/vc_row_inner][/vc_tta_section][vc_tta_section title=”Gallery” tab_id=”1587658012215-b3d32233-c55d”][vc_row_inner equal_height=”yes”][vc_column_inner][basel_title align=”left” title=”Videos”][/vc_column_inner][/vc_row_inner][vc_video link=”https://youtu.be/X3Z9SFJudlQ” el_width=”50″][/vc_tta_section][vc_tta_section title=”Brochure” tab_id=”1571372306223-1789746b-348b”][vc_row_inner equal_height=”yes”][vc_column_inner][basel_title align=”left” title=”Brochure”][/vc_column_inner][/vc_row_inner][vc_column_text]
| Biomime Morph™ | View |
|---|
[/vc_column_text][/vc_tta_section][vc_tta_section title=”Tech Specification” tab_id=”1587438314042-9c1293fb-9a57″][vc_row_inner equal_height=”yes”][vc_column_inner][basel_title align=”left” title=”Product Specifications”][/vc_column_inner][/vc_row_inner][vc_column_text]
| Stent material | Cobalt Chromium L605 |
|---|---|
| Stent architecture | Hybrid Cell Design with Non-Linear links |
| Stent Strut Thickness | 65 µm |
| Drug | Sirolimus |
| Polymer | Biodegradable + Biocompatible |
| Delivery system | Rapid Exchange |
| Drug Dose | 1.25μg/mm2 |
[/vc_column_text][vc_row_inner equal_height=”yes”][vc_column_inner][basel_title align=”left” title=”Size Chart”][/vc_column_inner][/vc_row_inner][vc_column_text]
| DIAMETER / LENGTH | 30MM | 40MM | 50MM | 60MM |
|---|---|---|---|---|
| MAIN BRANCH-SIDE BRANCH | ||||
| 2.75-2.25 mm | BIM27522530 | BIM27522540 | BIM27522550 | BIM27522560 |
| 3.00-2.50 mm | BIM30025030 | BIM30025040 | BIM30025050 | BIM30025060 |
| 3.50-3.00 mm | BIM35030030 | BIM35030040 | BIM35030050 | BIM35030060 |
[/vc_column_text][/vc_tta_section][vc_tta_section title=”Clinical Data” tab_id=”1587438616440-1d5130dc-ff41″][vc_row_inner equal_height=”yes”][vc_column_inner][basel_title align=”left” title=”Clinical Data”][/vc_column_inner][/vc_row_inner][vc_column_text]
| STUDY NAME | TYPE OF STUDY | TOTAL PATIENTS | STATUS | LINKS |
|---|---|---|---|---|
| SPONSOR INITIATED STUDIES | ||||
| Morph India Study | Prospective study | 450 | Ongoing | Know More |
| Morpheus-Global Registry | Prospective study | 400 | Ongoing | Know More |
| Morph-BGM Study | Prospective study | 100 | Ongoing | Know More |
| INVESTIGATOR INITIATED STUDIES | ||||
| BioMime Morph Multicenter study | Observational study | 362 | Completed | Know More |
| BioMime Morph study, Valencia, Spain | Prospective clinical cohort study | 50 | Completed | Know More |
| BioMime Morph study, Russia | Prospective, Observational study | 85 | Completed | Know More |
| BioMime Morph study, The Netherlands | Observational study | 49 | Completed | Know More |
| BioMime Morph study, Spain | Observational study | 628 | Completed | Know More |
[/vc_column_text][/vc_tta_section][/vc_tta_tabs][/vc_column][/vc_row]